Ruth Coleman

Picture of Ruth Coleman

Position:Senior Research Statistician

Telephone:01865 857253


Ruth is a Senior Research Statistician at the Diabetes Trials Unit.

Her ongoing projects include the expansion of the UKPDS Risk Engine to include estimates of both cardiovascular and microvascular disease risk, and modelling life expectancy in type 2 diabetes.

She is currently the statistical lead for the ACE study.

Latest publications

Predicting Post One-year Durability of Glucose-lowering Monotherapies in Patients with Newly-diagnosed Type 2 Diabetes Mellitus - A MASTERMIND Precision Medicine Approach (UKPDS 87)
Olorunsola F. Agbaje et al.
Diabetes Research and Clinical Practice 2020

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial
Hertzel C. Gerstein et al.
Diabetes Care 2020

Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA-REG OUTCOME Trial be Explained by the Changes Seen in Conventional Cardiovascular Risk Factor Levels?
Ruth L. Coleman et al.
Diabetes Obes Metab. 2020;22:1151-1156

Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Ernesto Maddaloni et al.
Lancet Diabetes Endocrinol 2020;8:206-15

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
Ruth L. Coleman et al.
Cardiovasc Diabetol 2019;18:135

Long-term Risk of Cardiovascular Disease in Individuals with Latent Autoimmune Diabetes of Adults (UKPDS 85)
E. Maddaloni et al.
Diabetes Obese Metab. 2019;2019:2115-2122